Fig. 5: ALOX15 pharmacological inhibition impairs human myogenic cells differentiation.
From: Bioactive lipid mediator class switching regulates myogenic cell progression and muscle regeneration
a–h Expression quantification by qPCR of the enzymes ALOX5 (a), ALOX5AP (b) (P vs. D3 p = 0.0037; P vs. D5 p = 0.0009; P vs. D7 p = 0.0008), PTGS2 (c) (P vs. D3 p = 0.0392), PTGDS (d) (P vs. D7 p = 0.0429), ALOX15 (e) (P vs. D3 p = 0.0089), and ALOX12 (f) in human myogenic cells during in vitro myogenesis. Pro-inflammatory enzymes are identified in red, pro-resolving enzymes are identified in green. g Growth curve of human myoblasts treated with the ALOX15 inhibitor PD146176 (10 μM, 20 μM) or vehicle (VEH) for 3 days in proliferation medium. h Representative images of human myogenic cells at 3 days of differentiation immunostained for Myosin heavy chain (MyHC, pink), Myog (green), and DAPI (blue). Scale bars = 50 μm. i Fusion index of human myoblasts treated with PD146176 (10 μM, 20 μM) or vehicle (VEH) for 3 days in differentiation medium (VEH vs. PD146176 10 uM p = 0.00141; VEH vs. PD146176 20 uM p = 0.0011). Results are expressed as mean +/- SEM. Biological replicates n = 3 for panels a–f; n = 5 for panels g, i. * p < 0.05, **p < 0.01, *** p < 0.001. One-way ANOVA with Dunnett’s multiple comparisons test (a–f). Repeated measure 2-way ANOVA with Uncorrected Fisher’s LSD multiple comparisons test (g). 2-way Paired t-test (i). Source data are provided as a Source Data file.
